Myocarditis
Q&A: Athletes with heart disease may yet compete; shared decision-making crucial
The American Heart Association and American College of Cardiology issued a scientific statement detailing clinical guidance on competitive sports participation for athletes with cardiovascular disease.
Top in cardiology: Benefits of time-restricted eating; new myocarditis treatment advisory
Time-restricted eating, particularly among people with underlying metabolic disorders, may confer benefits beyond weight loss, according to a speaker at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
Q&A: ACC unveils new staging system, decision pathway for myocarditis diagnosis, care
The American College of Cardiology recently issued an expert consensus document outlining a novel staging system and decision pathway for the diagnosis, treatment and longitudinal follow-up of patients with myocarditis.
Findings reveal ‘crucial’ need to manage immune checkpoint inhibitor-induced myocarditis
Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.
Sports cardiology roundup from ACC 2024: Return to play, occupational risks among hot topics
Return-to-play considerations and CVD risks of people who perform under life-threatening conditions were among the key sports cardiology topics at the American College of Cardiology Scientific Session in April in Atlanta.
COVID-19 vaccination lowers all-cause mortality risk by 82% among patients with HF
COVID-19 vaccination decreased the risk for CV events, hospitalization and death among patients with HF, according to a poster presented at the European Society of Cardiology’s Heart Failure 2024 meeting.
Despite advancements, EPGA management often remains 'a bit of a mystery'
DESTIN, Fla. — Treating respiratory and systemic manifestations of eosinophilic granulomatosis with polyangiitis can be effective despite an incomplete understanding of the disease, said a speaker at the Congress of Clinical Rheumatology East.
Study: IVIg lowers mortality in children with myocarditis
TORONTO — Use of IV immunoglobulin with or without steroids was associated with reduced mortality among children with myocarditis compared with steroids alone, according to a study presented at the Pediatric Academic Societies Meeting.
Anakinra safe but did not increase days free from acute myocarditis complications
Anakinra, an interleukin-1R antagonist, was shown to be a safe treatment in patients with acute myocarditis, but did not change the number of days free from complications compared with placebo, a speaker reported.
Oncologists play key role in diagnosing immune checkpoint inhibitor-induced myocarditis
Incidence of immune checkpoint inhibitor-induced myocarditis may increase as more patients receive immunotherapy. In this special report, Healio | HemOnc Today highlights how a multidisciplinary approach can reduce mortality through early recognition and prompt intervention.